Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P1075 is a small molecule vasodilator classified as an ATP-sensitive potassium channel opener (KATP channel opener or KATPCO)[1][2][6]. It induces relaxation of vascular smooth muscle by activating KATP channels, primarily by binding to sulfonylurea receptors SUR2A and SUR2B with high affinity (Kd of 17 nM and 3 nM, respectively)[1]. This mechanism leads to peripheral vasodilation, reduced blood pressure, and increased blood flow[2]. P1075 has been used as a research tool in cardiovascular studies and exhibits high potency (EC50 rat aorta relaxation = 7.5 nM)[1]. No approved clinical indications or marketed pharmaceutical products containing P1075 are known, and it is predominantly distributed by research chemical suppliers[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on p1075.